Reynders McVeigh Capital Management’s Charles River Laboratories CRL Stock Holding History

Reynders McVeigh Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-700	Closed	-$264K	–	232
2021 Q4	$264K	Sell	700 -50	-7%	-$19.4K	0.02%	206
2021 Q3	$310K	Sell	750 -125	-14%	-$51.9K	0.02%	187
2021 Q2	$324K	Sell	875 -75	-8%	-$25K	0.02%	189
2021 Q1	$275K	Sell	950 -150	-14%	-$41.7K	0.02%	199
2020 Q4	$275K	Buy	+1,100	New	+$262K	0.02%	194

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Reynders McVeigh Capital Management's CRL Position: Q1 2022 in Review

Reynders McVeigh Capital Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 700 shares — an estimated $264K sold.

Reynders McVeigh Capital Management first reported a position in CRL in Q4 2020 and held it in 5 quarters. The position peaked at $324K in Q2 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Reynders McVeigh Capital Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
Reynders McVeigh Capital Management sold 700 Charles River Laboratories shares in Q1 2022, an estimated $264K.
Reynders McVeigh Capital Management first reported a position in Charles River Laboratories in Q4 2020 and held it in 5 quarters.
Reynders McVeigh Capital Management's Charles River Laboratories position peaked at $324K in Q2 2021.
644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2022, filed 11 May 2022.